Edge Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
20 nov. 2015 16h05 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) (the “Company”), a clinical stage biotechnology company developing novel hospital-based therapies in...
Edge Therapeutics Reports Third Quarter 2015 Financial Results
06 nov. 2015 07h00 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the...
Edge Therapeutics Names W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary
05 nov. 2015 09h00 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management...
Edge Therapeutics to Present at the 24th Annual Credit Suisse Healthcare Conference
04 nov. 2015 09h00 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Nov. 04, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management...
Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients With Subarachnoid Hemorrhage
12 oct. 2015 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that the European Commission (EC) has granted orphan drug designation to...
Edge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
06 oct. 2015 16h05 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Oct. 06, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) (“Edge”) today announced the closing of its initial public offering of 8,412,423 shares of its...
Edge Therapeutics Announces Pricing of Its Initial Public Offering
30 sept. 2015 20h33 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced the pricing of its initial public offering of 7,315,151 shares of its common...